- Home
- DRIO vs ICCC Comparison
DRIO vs ICCC Comparison
Compare DRIO & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRIO
- ICCC
- Stock Information
- Founded
- DRIO 2011
- ICCC 1982
- Country
- DRIO United States
- ICCC United States
- Employees
- DRIO N/A
- ICCC N/A
- Industry
- DRIO Medical/Dental Instruments
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- DRIO Health Care
- ICCC Health Care
- Exchange
- DRIO Nasdaq
- ICCC Nasdaq
- Market Cap
- DRIO 25.1M
- ICCC 28.7M
- IPO Year
- DRIO N/A
- ICCC 1987
- Fundamental
- Price
- DRIO $1.13
- ICCC $3.66
- Analyst Decision
- DRIO Strong Buy
- ICCC
- Analyst Count
- DRIO 1
- ICCC 0
- Target Price
- DRIO $4.00
- ICCC N/A
- AVG Volume (30 Days)
- DRIO 123.1K
- ICCC 48.1K
- Earning Date
- DRIO 10-31-2024
- ICCC 11-11-2024
- Dividend Yield
- DRIO N/A
- ICCC N/A
- EPS Growth
- DRIO N/A
- ICCC N/A
- EPS
- DRIO N/A
- ICCC N/A
- Revenue
- DRIO $19,147,000.00
- ICCC $23,222,929.00
- Revenue This Year
- DRIO $36.40
- ICCC N/A
- Revenue Next Year
- DRIO $35.93
- ICCC N/A
- P/E Ratio
- DRIO N/A
- ICCC N/A
- Revenue Growth
- DRIO N/A
- ICCC 48.05
- 52 Week Low
- DRIO $0.68
- ICCC $3.34
- 52 Week High
- DRIO $3.32
- ICCC $5.59
- Technical
- Relative Strength Index (RSI)
- DRIO 62.33
- ICCC 48.56
- Support Level
- DRIO $0.95
- ICCC $3.50
- Resistance Level
- DRIO $1.16
- ICCC $3.90
- Average True Range (ATR)
- DRIO 0.09
- ICCC 0.22
- MACD
- DRIO 0.02
- ICCC 0.01
- Stochastic Oscillator
- DRIO 89.80
- ICCC 57.14
About DRIO DarioHealth Corp.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.